Clinical Trials Logo

Philadelphia Chromosome clinical trials

View clinical trials related to Philadelphia Chromosome.

Filter by:

NCT ID: NCT01131325 Terminated - CML Clinical Trials

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

MACS1148
Start date: October 21, 2010
Phase: Phase 4
Study type: Interventional

This study is to determine the number of European Leukemia Network (ELN)guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations treated with nilotinib.

NCT ID: NCT01066468 Terminated - Clinical trials for Chronic Myeloid Leukemia (CML)

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens

NCT ID: NCT00905398 Terminated - Clinical trials for Acute Lymphoblastic Leukemia

Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

ALLPhi
Start date: May 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with acute lymphoblastic leukemia and positivity for the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) protein or the Philadelphia chromosome have a poor prognosis with standard chemotherapy. The prognosis seemed to improve following the adition of imatinibe, a BCR-ABL inhibitor, to the treatment but still a substantial amount of patients relapse or progress during treatment. Nilotinib is a BCR-ABL inhibitor more potent than imatinib. It has been shown to be effective against most of the cells that bear mutations of the BCR-ABL protein leading to resistance to imatinibe. The investigators' hypothesis is that the addition of nilotinib to a standard chemotherapy for acute lymphoblastic leukemia (ALL) will translate into more rapid BCR-ABL reduction and effectiveness against imatinib-resistant clones leading to less relapses and better survival.

NCT ID: NCT00860535 Terminated - Clinical trials for Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)

Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)

Start date: June 2009
Phase: Phase 1
Study type: Interventional

This study will evaluate a gene expression signature (Growth Factor Signature [GFS]) as a biomarker for response/resistance to BRC-ABL oncogene inhibitors.

NCT ID: NCT00644878 Terminated - Clinical trials for Chronic Myelogenous Leukemia - Chronic Phase

Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib

MACS0254
Start date: October 2008
Phase: Phase 2
Study type: Interventional

This exploratory study will evaluate the change in molecular response in chronic myelogenous leukemia - chronic phase patients with a complete cytogenetic response and have a suboptimal molecular response to imatinib

NCT ID: NCT00500006 Terminated - Clinical trials for Chronic Myelogenous Leukemia

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Start date: October 2007
Phase: Phase 1
Study type: Interventional

This study will evaluate MK0457 in combination with Dasatinib in patients with Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Efficacy and Safety will be evaluated.

NCT ID: NCT00464113 Terminated - Clinical trials for Chronic Myeloid Leukemia

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

Start date: May 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228.